Sunil R. Lakhani
A5047329745- Cancer Genomics and Diagnostics
- Breast Lesions and Carcinomas
- Breast Cancer Treatment Studies
- Cancer and Skin Lesions
- BRCA gene mutations in cancer
- Genetic factors in colorectal cancer
- Cancer Cells and Metastasis
- Genomic variations and chromosomal abnormalities
- DNA Repair Mechanisms
- Gene expression and cancer classification
- Molecular Biology Techniques and Applications
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Cancer-related Molecular Pathways
- Brain Metastases and Treatment
- Genomics and Chromatin Dynamics
- RNA modifications and cancer
- Cancer-related molecular mechanisms research
- Epigenetics and DNA Methylation
- Salivary Gland Tumors Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Cancer Diagnosis and Treatment
- Cancer-related gene regulation
- Bioinformatics and Genomic Networks
The University of Queensland
2016-2025
Royal Brisbane and Women's Hospital
2016-2025
Queensland Health
2012-2025
Nirma University
2024
Peter MacCallum Cancer Centre
2008-2023
Keele University
2023
QIMR Berghofer Medical Research Institute
2005-2019
Olivia Newton-John Cancer Wellness & Research Centre
2019
Austin Health
2019
Garvan Institute of Medical Research
2019
Poly(adenosine diphosphate–ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence patients BRCA1 or BRCA2 germline mutation–associated early breast cancer.
PURPOSE To update key recommendations of the American Society Clinical Oncology/College Pathologists estrogen (ER) and progesterone receptor (PgR) testing in breast cancer guideline. METHODS A multidisciplinary international Expert Panel was convened to clinical practice guideline informed by a systematic review medical literature. RECOMMENDATIONS The continues recommend ER invasive cancers validated immunohistochemistry as standard for predicting which patients may benefit from endocrine...
PURPOSE: The morphologic and molecular phenotype of breast cancers may help identify patients who are likely to carry germline mutations in BRCA1 BRCA2. This study evaluates the immunohistochemical profiles tumors arising with these genes. MATERIALS AND METHODS: Samples obtained from International Breast Cancer Linkage Consortium were characterized morphologically immunohistochemically using antibodies estrogen receptor, progesterone HER-2 (c-erbB-2 oncogene), p53 protein. RESULTS: more...
The classification of breast tumours continues to evolve, with the integration new knowledge from research rapidly being translated into clinical practice. Major changes are shown in Table 1. In this volume World Health Organization (WHO) series’ fifth edition, which is an update fourth-edition published 2012,1 descriptions follow familiar systematic approach previous volumes, content now organised sequence benign epithelial proliferations and precursors, through neoplasms, in-situ invasive...
Background : We have previously demonstrated that breast cancers associated with inherited BRCA1 and BRCA2 gene mutations differ from each other in their histopathologic appearances of these types differs patients unselected for family history (i.e., sporadic cancers). now conducted a more detailed examination cytologic architectural features tumors. Methods Specimens tumor tissue (5-µm-thick sections) were examined independently by two pathologists, who unaware the case or control subject...
To investigate the proportion of breast cancers arising in patients with germ line BRCA1 and BRCA2 mutations expressing basal markers developing predictive tests for identification high-risk patients.Histopathologic material from 182 tumors mutation carriers, 63 109 controls, collected as part international Breast Cancer Linkage Consortium were immunohistochemically stained CK14, CK5/6, CK17, epidermal growth factor receptor (EGFR), osteonectin.All five commoner than control (CK14: 61%...
To study the toxicity and pharmacokinetic-pharmacodynamic profile of 17-allylamino, 17- demethoxygeldanamycin (17-AAG) to recommend a dose for phase II trials.This was I examining once-weekly dosing schedule 17-AAG. Thirty patients with advanced malignancies were treated.The highest level reached 450 mg/m(2)/week. The dose-limiting toxicities (DLTs) encountered grade 3 diarrhea in three (one at 320 mg/m(2)/week two mg/m(2)/week) 4 hepatotoxicity (AST/ALT) one patient Two nine DLTs level....
Abstract Protein kinases are frequently mutated in human cancer and inhibitors of mutant protein have proven to be effective anticancer drugs. We screened the coding sequences 518 (∼1.3 Mb DNA per sample) for somatic mutations 26 primary lung neoplasms seven cell lines. One hundred eighty-eight were detected 141 genes. Of these, 35 synonymous (silent) changes. This result indicates that most 188 “passenger” not causally implicated oncogenesis. However, an excess ∼40 nonsynonymous...
Introduction The human genome is peppered with mobile repetitive elements called long interspersed nuclear element–1 (L1) retrotransposons. Propagating through RNA and cDNA intermediates, these molecular parasites copy insert themselves throughout the genome, potentially disruptive effects on neighboring genes or regulatory sequences. In germ line, unique sequence downstream of L1 can also be retrotransposed if transcription continues beyond repeat, a process known as 3′ transduction. There...
BackgroundRetrospective studies provide conflicting interpretations of the effect inherited genetic factors on prognosis patients with breast cancer. The primary aim this study was to determine a germline BRCA1 or BRCA2 mutation cancer outcomes in young-onset cancer.MethodsWe did prospective cohort female recruited from 127 hospitals UK aged 40 years younger at first diagnosis (by histological confirmation) invasive Patients previous malignancy (except non-melanomatous skin cancer) were...
Cytokeratin (CK) 14, a myoepithelial marker, is also expressed in proportion of breast carcinomas. There evidence that these tumours show differing metastatic pattern and clinical outcome from other invasive ductal carcinomas (IDCs) may need different management. Currently, they are not identified routine practice no morphological guidelines exist to aid their identification. The aim this study was analyse the histological features CK14+ IDC.A detailed review 453 grade 3 IDCs revealed 88...